Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), said an abstract covering preliminary results from an ongoing study of crofelemer in adults with short bowel syndrome with intestinal failure has been accepted for presentation at the American College of Gastroenterology Annual Scientific Meeting.
ACG 2026 is scheduled to take place from October 9 to October 14 in Nashville, Tennessee.
The abstract relates to an ongoing open-label study evaluating crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure, or SBS-IF.
The supplied information does not provide the preliminary results that will be presented at the meeting.
Separate Phase 2 Crofelemer Trial Underway
Napo is separately conducting a multicentre, randomised, double-blind, placebo-controlled Phase 2 clinical trial of crofelemer in adult Type 1 SBS patients without colon-in-continuity.
Results from the Phase 2 study are expected during the first half of 2027.
Crofelemer remains investigational for the indications described in the supplied material, and the expected timing of study results does not indicate the outcome of the trial.
Paediatric Study Data Presented in June
In June 2026, data from ongoing investigational studies of oral liquid crofelemer in paediatric patients with intestinal failure resulting from microvillus inclusion disease, or MVID, and SBS-IF were presented at the 58th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting in Lille, France.
According to the supplied information, the studies showed reductions in weekly parenteral support requirements among paediatric patients who had received oral crofelemer for more than one year.
No significant clinical or laboratory abnormalities were reported in those patients, according to the study information provided.
Jaguar Plans MVID Regulatory Filing in 2027
Jaguar Health has said it plans to submit a New Drug Application for crofelemer for MVID in mid-2027.
Patients with intestinal failure, including those with SBS or MVID, can require total parenteral nutrition, with or without supplemental intravenous fluids. Such support can be required for as many as seven days per week and more than 20 hours per day.
The planned regulatory submission remains subject to the company’s development programme and does not indicate whether the application will be accepted or approved.